Envestnet Asset Management Inc. Has $90.57 Million Holdings in Aflac Incorporated (NYSE:AFL)

Envestnet Asset Management Inc. boosted its holdings in shares of Aflac Incorporated (NYSE:AFL - Free Report) by 1.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 814,586 shares of the financial services provider's stock after purchasing an additional 11,877 shares during the quarter. Envestnet Asset Management Inc. owned about 0.15% of Aflac worth $90,574,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Norges Bank purchased a new stake in shares of Aflac in the 4th quarter worth $349,699,000. GAMMA Investing LLC grew its stake in Aflac by 12,313.9% during the 1st quarter. GAMMA Investing LLC now owns 1,504,067 shares of the financial services provider's stock valued at $167,237,000 after purchasing an additional 1,491,951 shares during the last quarter. Northern Trust Corp boosted its stake in shares of Aflac by 22.9% in the fourth quarter. Northern Trust Corp now owns 7,296,014 shares of the financial services provider's stock worth $754,700,000 after buying an additional 1,357,753 shares during the last quarter. Vanguard Group Inc. boosted its position in Aflac by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 51,340,298 shares of the financial services provider's stock worth $5,310,640,000 after purchasing an additional 653,275 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Aflac by 11.9% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,250,905 shares of the financial services provider's stock worth $543,154,000 after purchasing an additional 556,394 shares in the last quarter. Institutional investors own 67.44% of the company's stock.

Aflac Stock Up 1.1%

AFL stock traded up $1.12 during mid-day trading on Monday, hitting $102.69. The stock had a trading volume of 2,048,436 shares, compared to its average volume of 2,154,816. Aflac Incorporated has a 1-year low of $92.44 and a 1-year high of $115.50. The company has a fifty day moving average of $103.79 and a 200 day moving average of $105.26. The company has a current ratio of 0.09, a quick ratio of 0.09 and a debt-to-equity ratio of 0.29. The stock has a market capitalization of $55.52 billion, a price-to-earnings ratio of 16.05, a PEG ratio of 3.14 and a beta of 0.81.

Aflac (NYSE:AFL - Get Free Report) last posted its earnings results on Wednesday, April 30th. The financial services provider reported $1.66 earnings per share for the quarter, missing the consensus estimate of $1.67 by ($0.01). The company had revenue of $3.40 billion for the quarter, compared to the consensus estimate of $4.53 billion. Aflac had a net margin of 21.27% and a return on equity of 15.55%. Aflac's quarterly revenue was down 37.5% on a year-over-year basis. During the same quarter last year, the business earned $1.66 earnings per share. On average, equities analysts expect that Aflac Incorporated will post 6.88 EPS for the current fiscal year.

Aflac Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, June 2nd. Shareholders of record on Wednesday, May 21st were issued a dividend of $0.58 per share. This represents a $2.32 dividend on an annualized basis and a yield of 2.26%. The ex-dividend date of this dividend was Wednesday, May 21st. Aflac's payout ratio is 36.25%.

Insider Transactions at Aflac

In other news, Director Arthur Reginald Collins sold 2,750 shares of the business's stock in a transaction that occurred on Thursday, May 15th. The stock was sold at an average price of $105.70, for a total value of $290,675.00. Following the transaction, the director directly owned 6,728 shares of the company's stock, valued at $711,149.60. The trade was a 29.01% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Masatoshi Koide sold 37,000 shares of the company's stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $105.59, for a total value of $3,906,830.00. Following the transaction, the director directly owned 70,992 shares in the company, valued at approximately $7,496,045.28. This represents a 34.26% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 40,750 shares of company stock valued at $4,304,295 in the last three months. 0.80% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

AFL has been the subject of several recent research reports. Raymond James Financial cut their price target on Aflac from $115.00 to $110.00 and set an "outperform" rating for the company in a report on Thursday, May 29th. UBS Group raised their price target on Aflac from $109.00 to $114.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 2nd. Barclays set a $98.00 target price on Aflac and gave the company an "underweight" rating in a report on Monday, July 7th. Piper Sandler lifted their target price on Aflac from $118.00 to $124.00 and gave the company an "overweight" rating in a report on Wednesday, April 2nd. Finally, JPMorgan Chase & Co. raised their price target on Aflac from $96.00 to $100.00 and gave the company a "neutral" rating in a research note on Tuesday, July 8th. Three equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus price target of $107.07.

About Aflac

Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. The company operates through Aflac Japan and Aflac U.S. segments. The Aflac Japan segment offers cancer, medical, nursing care, work leave, GIFT, and whole and term life insurance products, as well as WAYS and child endowment plans under saving type insurance products in Japan.